InvestorWire NewsRoom


Imagin Medical (CSE: IME) (OTCQB: IMEXF), With Their Advanced i/Blue(TM) Imaging System, Closes Second Tranche of Convertible Note Offering
March 17, 2021

Imagin Medical (CSE: IME) (OTCQB: IMEXF), With Their Advanced i/Blue(TM) Imaging System, Closes Second Tranche of Convertible Note Offering

  • Imagin Medical is a surgical company focused on developing its i/Blue(TM) Imaging System, employing patented ultrasensitive imaging technology
  • The i/Blue(TM) Imaging System is system compatible; system attaches to most endoscopes
  • The company recently closed the second tranche for the amount of US$1,415,500 of the Convertible Note offering

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive surgical procedures. Imagin Medical is run by an experienced management team that is preparing their i/Blue(TM) Imaging System for the industry. An FDA approval process is underway.

The company’s patented ultrasensitive imaging product, the i/Blue(TM) Imaging System, based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.

The Patented i/Blue(TM) Imaging System

White light cystocopy does not always discern cancer from healthy tissue. The company hopes to overcome this handicap using its advanced patented ultrasensitive imaging product, the i/Blue(TM) Imaging System (

Imagin Medical uses Blue Light technology that combines the improved image quality of blue light with the location orientation that white light provides. The device uses an already FDA-approved contrast agent, that is administered through a catheter one hour before the surgery.

The i/Blue(TM) Imaging System is compatible with most endoscopes through the plug-and-play method. The surgeon can simultaneously view both white and blue light video streams in a single frame and in real-time on the surgical monitor, without having to toggle between the two images. The company believes this breakthrough technology will advance the accuracy and efficiency of bladder cancer detection and removal. And potentially reduce bladder cancer recurrence rates and as well as healthcare costs (

In a recent announcement made by Imagin Medical, the company stated that it has closed the second tranche of US$1,415,500 of the Convertible Note offering. Total Convertible Note amount of $2,165,500 raised earlier this year (

Imagin Medical’s Focus on Surgical Imaging Market

The global endoscopy market is valued at $46B. Imagin’s bladder cancer target is estimated to be a $400M slice of this market. The demand for improved visualization during Minimally Invasive Surgery (“MIS”) has increased manifold in recent years. MIS is less painful, offers speedy recovery, and cost-savings.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).